Company Filing History:
2 out of 22 
2 out of 5,089 
2 out of 4 Years Active: 2010-2014
Title: The Innovations of Daniel Perrissoud: A Pioneer in Ghrelin Analogue Ligands
Introduction
Daniel Perrissoud, an accomplished inventor based in Bad Homburg, Germany, has significantly contributed to the field of pharmaceuticals with his innovative work on ghrelin analogue ligands. With two patents to his name, Perrissoud's inventions are poised to impact treatments for various physiological and pathophysiological conditions.
Latest Patents
Perrissoud's latest patents focus on novel triazole derivatives that serve as ghrelin analogue ligands of growth hormone secretagogue receptors. The inventions provide important advancements in treating conditions mediated by GHS receptors. His research highlights the effectiveness of these compounds in addressing issues such as growth retardation, cachexia, energy balance regulation, obesity, and diabetes. Furthermore, his work with GHS receptor antagonists and agonists presents promising solutions for various inflammatory effects and postoperative complications.
Career Highlights
Throughout his career, Daniel Perrissoud has worked with reputable organizations, notably Zentaris GmbH and the Centre National De La Recherche Scientifique. His experiences in these institutions have allowed him to harness his expertise and translate complex scientific concepts into practical applications.
Collaborations
Perrissoud has collaborated with distinguished colleagues, including Jean Martinez and Aline Moulin. Their teamwork has fostered innovation and contributed to the advancement of therapeutic options in the field of ghrelin receptor research.
Conclusion
Daniel Perrissoud exemplifies the spirit of innovation, with his groundbreaking patents addressing critical health challenges. His contributions to the pharmaceutical industry pave the way for future advancements, particularly in the treatment of conditions related to growth hormone secretagogue receptors.